Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call PR Newswire RED BANK, N.J., March 13, 2023 RED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention...
Provention Bio Announces the Grant of Inducement Awards PR Newswire RED BANK, N.J., March 3, 2023 RED BANK, N.J., March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the...
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 PR Newswire RED BANK, N.J., Feb. 23, 2023 RED BANK, N.J., Feb. 23, 2023 /PRNewswire/ -- Provention...
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US PR Newswire RED BANK, N.J., Feb. 13, 2023 Companies collaborating to expand access to TZIELD™...
Provention Bio to Present at the SVB Securities Global Biopharma Conference PR Newswire RED BANK, N.J., Feb. 8, 2023 RED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:...
Provention Bio Announces the Grant of Inducement Awards PR Newswire RED BANK, N.J., Feb. 3, 2023 RED BANK, N.J., Feb. 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company...
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD® PR Newswire RED BANK, N.J., Feb. 2, 2023 RED BANK, N.J., Feb. 2, 2023...
Provention Bio Announces the Grant of Inducement Awards PR Newswire RED BANK, N.J., January 6, 2023 RED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the...
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors PR Newswire RED BANK, N.J., Jan. 5, 2023 RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:...
Provention Bio Announces the Grant of Inducement Awards PR Newswire RED BANK, N.J., Dec. 2, 2022 RED BANK, N.J., Dec. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales